Biotechnology startup Code Biotherapeutics Inc. has raised $75 million in new venture capital to develop genetic medicines based on technology designed to make these types of treatments more ...

Photo: Google DeepMind One of the greatest challenges biologists face is figuring out which of the myriad variations in a person’s genetic code might make them sick.

The genetic code acts as life’s instruction manual, telling cells how to build proteins from DNA and RNA. Though it's a marvel of molecular precision, the path it took to evolve remains unclear ...

23andMe stock is down over 95% from its peak, cutting its value from $6 billion to $345 million. The genetic-testing company is facing financial and strategic challenges, and was hacked last year.

Code Bio’s approach to delivering genetic medicines is based on synthetic DNA. To that structure, the company can add targeting molecules—peptides, antibodies, or small molecules.

The genetic code acts as life’s instruction manual, telling cells how to build proteins from DNA and RNA. Though it's a marvel of molecular precision, the path it took to evolve remains unclear ...